Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The abundance and effects of structural variation at BRCA1/2 in tumors are not well understood. In particular, the impact of these events on homologous recombination repair deficiency (HRD) has yet to be demonstrated.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Cancer Res

Title: Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher: American Association for Cancer Research (AACR)

ISSN (Electronic): 1557-3265

ISSN (Print): 1078-0432

Publication date (Electronic): June 01 2021

Volume: 27

Issue: 11

Affiliations

[1 ] MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom. ailith.ewing@igmm.ed.ac.uk.

[2 ] MRC Human Genetics Unit, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.

[3 ] Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.

[4 ] Edinburgh Pathology, Cancer Research UK Edinburgh Centre, MRC IGMM, University of Edinburgh, Edinburgh, Scotland, United Kingdom.

[5 ] Department of Oncology, Ninewells Hospital, NHS Tayside, Dundee, Scotland, United Kingdom.

[6 ] Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, Scotland, United Kingdom.

[7 ] Department of Oncology, Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom.

[8 ] Institute of Education for Medical and Dental Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, Scotland, United Kingdom.

[9 ] Department of Oncology, Raigmore Hospital, NHS Highland, Inverness, Scotland, United Kingdom.

[10 ] Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom.

[11 ] Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.

[12 ] Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, Scotland, United Kingdom.

[13 ] Edinburgh Cancer Centre, Western General Hospital, NHS Lothian, Edinburgh, Scotland, United Kingdom.

[14 ] Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, England, United Kingdom.

[15 ] Precision Medicine Scotland (PMS-IC), Queen Elizabeth University Hospital, Glasgow, Scotland, United Kingdom.

[16 ] Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, England, United Kingdom.

[17 ] Translational Medicine, Oncology R&D, AstraZeneca, Waltham, Massachusetts.

[18 ] Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.

[19 ] West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom.

[20 ] South Western Sydney Clinical School, Faculty of Medicine, University of NSW, Liverpool, New South Wales, Australia.

Article

Publisher Item ID: 1078-0432.CCR-20-4068 Mid ID: EMS121115

DOI: 10.1158/1078-0432.CCR-20-4068

PMC ID: 7610896

PubMed ID: 33741650

SO-VID: dccde81c-eae3-496b-b38d-d79cdd0b58cc

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.